The analysis revealed that the presence of CD56+, CD8+, PD-1+, and PD-L1+ cells within the tumor microenvironment serves as a harbinger of a favorable therapeutic response, demonstrating a significant association with extended patient survival (Supplementary Figure S6). The gene discussed is PDCD1; the disease is neoplasm.